QT
APLS

Quantamental Technologies’s Apellis Pharmaceuticals APLS Stock Holding History

Quantamental Technologies’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-274
Closed -$5K – 1450
2019
Q1 		$5K Sell
274
-330
-55% -$5.19K ﹤0.01% 1315
2018
Q4 		$8K Buy
+604
New +$9.27K ﹤0.01% 1172

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Quantamental Technologies's APLS Position: Q2 2019 in Review

Quantamental Technologies sold out of Apellis Pharmaceuticals (APLS) in Q2 2019, closing a stake of 274 shares — an estimated $5K sold.

Quantamental Technologies first reported a position in APLS in Q4 2018 and held it in 2 quarters. The position peaked at $8K in Q4 2018. 99 funds tracked by Wall St. Rank hold APLS as of Q2 2019.

  • Quantamental Technologies reported no remaining Apellis Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Quantamental Technologies sold 274 Apellis Pharmaceuticals shares in Q2 2019, an estimated $5K.
  • Quantamental Technologies first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Quantamental Technologies's Apellis Pharmaceuticals position peaked at $8K in Q4 2018.
  • 99 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2019.

Based on Quantamental Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.